Cochlear , the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Bailey from Morgan Stanley maintained a Sell rating on the stock and has a A$280.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Bailey has given his Sell rating due to a combination of factors impacting Cochlear’s financial outlook. One of the primary reasons is the company’s guidance for FY26 net profit after tax (NPAT), which suggests a significant reliance on the second half of the fiscal year for growth. This reliance is based on the anticipated launch of the Nexa implant, which introduces uncertainty regarding the timing and success of its market uptake.
Additionally, Morgan Stanley’s forecasts indicate a slight underperformance in NPAT compared to Visible Alpha’s expectations for the first half of FY26. This potential shortfall raises concerns about Cochlear’s ability to meet its full-year guidance, particularly if the Nexa implant does not perform as expected. These factors contribute to a cautious outlook, prompting the Sell rating on Cochlear’s stock.
According to TipRanks, Bailey is a 4-star analyst with an average return of 13.9% and a 46.97% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Cochlear , Telix Pharmaceuticals, and Ansell.